COMMUNIQUÉS West-GlobeNewswire

Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight Management
14/09/2026
BOSTON and COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, [...]
Revelyx Bio Reports Positive Topline Phase 2 Results for YY003, a Recombinant, Ready-to-Use Liquid Botulinum Toxin Type A, in Moderate-to-Severe Glabellar Lines
14/09/2026
Study met its primary endpoints: 80.8% of participants receiving 40 U achieved the composite response at Week 4 versus 0% with vehicle (p<0.001); YY003 was well tolerated, with no treatment-related serious adverse [...]
Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology
14/09/2026
Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “ [...]
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
14/09/2026
Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a [...]
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
14/09/2026
Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to [...]
Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness
14/09/2026
Alignment Reached on Key Elements of the Phase 3 Program to Support a 505(b)(2) NDA Submission 10XB-101 Now has Clear Regulatory Path Forward LA JOLLA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics (“ [...]
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
14/09/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1 st to align on RAD101Phase 3 pivotal trial protocol Brain [...]
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
14/09/2026
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia [...]
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
14/09/2026
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI- [...]
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
14/09/2026
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor Seventh consecutive positive DSMB recommendation reinforces [...]
Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
14/09/2026
Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 2027 [...]
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
14/09/2026
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE [...]
Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California
14/09/2026
New high-potency transdermal balm was created with professional athletes in mind and is suitable for both high-performance recovery and everyday use LONG BEACH, Calif. and TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- [...]
As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers
14/09/2026
Fashion industry shift puts new focus on bio-based and innovative textiles as Kraig Labs scales recombinant spider silk for potential luxury and performance applications ANN ARBOR, Mich., Sept. 14, 2026 (GLOBE NEWSWIRE [...]
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
14/09/2026
Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential [...]
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
14/09/2026
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - [...]
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
14/09/2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 [...]
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
14/09/2026
RALEIGH, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Slate Medicines Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and [...]
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
14/09/2026
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum